Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Neurol
Hoofdauteurs: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2018
Onderwerpen:
Neurology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items